ATLANTIC is a phase 2, open-label, single-arm trial that assessed the effect of durvalumab as a third-line or later treatment for advanced non-small cell lung cancer in patients with EGFR mutations or ALK rearrangements. Here, EGFR is linked to non-small cell lung carcinoma.